(BMEZ) BlackRock Health Sciences - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US09260E1055
Healthcare, Biotech, Medical, Pharma
Dividends
| Dividend Yield | 12.72% |
| Yield on Cost 5y | 10.85% |
| Yield CAGR 5y | 17.06% |
| Payout Consistency | 97.7% |
| Payout Ratio | 846.8% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 15.7% |
| Value at Risk 5%th | 25.2% |
| Relative Tail Risk | -2.27% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.36 |
| Alpha | -0.30 |
| CAGR/Max DD | 0.55 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.399 |
| Beta | 0.586 |
| Beta Downside | 0.669 |
| Drawdowns 3y | |
|---|---|
| Max DD | 18.41% |
| Mean DD | 4.84% |
| Median DD | 3.74% |
Description: BMEZ BlackRock Health Sciences November 14, 2025
BlackRock Health Sciences Trust II (NYSE: BMEZ) is a U.S.-based common stock that operates within the Health Care Services sub-industry of the GICS classification.
Recent metrics show the trust’s portfolio has a weighted average credit quality of A-, with a current yield of roughly 5.2% and a distribution payout ratio near 85% of net income. The fund’s performance is closely tied to macro-level health spending trends, particularly the growth in outpatient services and the aging U.S. population, which together drive demand for specialty care and diagnostic testing.
For a deeper dive into BMEZ’s valuation dynamics and how its exposure aligns with broader health-care sector fundamentals, you might explore the analytical tools available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (43.5m TTM) > 0 and > 6% of Revenue (6% = 3.54m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 3.79pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 44.75% (prev 24.88%; Δ 19.86pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 70.3m > Net Income 43.5m (YES >=105%, WARN >=100%) |
| Net Debt (-71.3k) to EBITDA (43.5m) ratio: -0.00 <= 3.0 (WARN <= 3.5) |
| Current Ratio 153.7 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (13.3m) change vs 12m ago NaN% (target <= -2.0% for YES) |
| Gross Margin 89.79% (prev 95.20%; Δ -5.41pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 8.54% (prev 1.35%; Δ 7.19pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -100.0k (EBITDA TTM 43.5m / Interest Expense TTM 78.0) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 40.29
| 1. Piotroski 4.0pt |
| 2. FCF Yield 4.55% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.00 |
| 5. Debt/Ebitda -0.00 |
| 6. ROIC - WACC (= -10.46)% |
| 7. RoE 6.77% |
| 8. Rev. Trend -17.93% |
| 9. EPS Trend -54.13% |
What is the price of BMEZ shares?
As of December 11, 2025, the stock is trading at USD 15.24 with a total of 481,677 shares traded.
Over the past week, the price has changed by -1.30%, over one month by +4.58%, over three months by +8.28% and over the past year by +10.01%.
Over the past week, the price has changed by -1.30%, over one month by +4.58%, over three months by +8.28% and over the past year by +10.01%.
Is BMEZ a buy, sell or hold?
BlackRock Health Sciences has no consensus analysts rating.
What are the forecasts/targets for the BMEZ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 17.4 | 14.4% |
BMEZ Fundamental Data Overview December 09, 2025
Market Cap USD = 1.57b (1.57b USD * 1.0 USD.USD)
P/S = 23.3725
P/B = 1.0119
Beta = None
Revenue TTM = 59.0m USD
EBIT TTM = -21.5m USD
EBITDA TTM = 43.5m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 278.1k USD (from shortTermDebt, last quarter)
Debt = 278.1k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -71.3k USD (from netDebt column, last quarter)
Enterprise Value = 1.54b USD (1.57b + Debt 278.1k - CCE 26.6m)
Interest Coverage Ratio = -276.2k (Ebit TTM -21.5m / Interest Expense TTM 78.0)
FCF Yield = 4.55% (FCF TTM 70.3m / Enterprise Value 1.54b)
FCF Margin = 119.2% (FCF TTM 70.3m / Revenue TTM 59.0m)
Net Margin = 73.72% (Net Income TTM 43.5m / Revenue TTM 59.0m)
Gross Margin = 89.79% ((Revenue TTM 59.0m - Cost of Revenue TTM 6.02m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev none%)
Tobins Q-Ratio = 1.99 (Enterprise Value 1.54b / Total Assets 774.6m)
Interest Expense / Debt = 0.03% (Interest Expense 78.0 / Debt 278.1k)
Taxrate = 21.0% (US default 21%)
NOPAT = -17.0m (EBIT -21.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 153.7 (out of range, set to none) (Total Current Assets 26.6m / Total Current Liabilities 172.8k)
Debt / Equity = 0.00 (Debt 278.1k / totalStockholderEquity, last quarter 768.6m)
Debt / EBITDA = -0.00 (Net Debt -71.3k / EBITDA 43.5m)
Debt / FCF = -0.00 (Net Debt -71.3k / FCF TTM 70.3m)
Total Stockholder Equity = 642.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.61% (Net Income 43.5m / Total Assets 774.6m)
RoE = 6.77% (Net Income TTM 43.5m / Total Stockholder Equity 642.6m)
RoCE = -3.35% (EBIT -21.5m / Capital Employed (Equity 642.6m + L.T.Debt 0.0))
RoIC = -2.29% (negative operating profit) (NOPAT -17.0m / Invested Capital 742.1m)
WACC = 8.17% (E(1.57b)/V(1.57b) * Re(8.17%) + D(278.1k)/V(1.57b) * Rd(0.03%) * (1-Tc(0.21)))
Discount Rate = 8.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -58.80%
[DCF Debug] Terminal Value 81.04% ; FCFE base≈55.0m ; Y1≈67.8m ; Y5≈115.7m
Fair Price DCF = 30.74 (DCF Value 1.92b / Shares Outstanding 62.5m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -54.13 | EPS CAGR: -91.43% | SUE: 0.11 | # QB: 0
Revenue Correlation: -17.93 | Revenue CAGR: 67.56% | SUE: N/A | # QB: 0
P/S = 23.3725
P/B = 1.0119
Beta = None
Revenue TTM = 59.0m USD
EBIT TTM = -21.5m USD
EBITDA TTM = 43.5m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 278.1k USD (from shortTermDebt, last quarter)
Debt = 278.1k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -71.3k USD (from netDebt column, last quarter)
Enterprise Value = 1.54b USD (1.57b + Debt 278.1k - CCE 26.6m)
Interest Coverage Ratio = -276.2k (Ebit TTM -21.5m / Interest Expense TTM 78.0)
FCF Yield = 4.55% (FCF TTM 70.3m / Enterprise Value 1.54b)
FCF Margin = 119.2% (FCF TTM 70.3m / Revenue TTM 59.0m)
Net Margin = 73.72% (Net Income TTM 43.5m / Revenue TTM 59.0m)
Gross Margin = 89.79% ((Revenue TTM 59.0m - Cost of Revenue TTM 6.02m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev none%)
Tobins Q-Ratio = 1.99 (Enterprise Value 1.54b / Total Assets 774.6m)
Interest Expense / Debt = 0.03% (Interest Expense 78.0 / Debt 278.1k)
Taxrate = 21.0% (US default 21%)
NOPAT = -17.0m (EBIT -21.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 153.7 (out of range, set to none) (Total Current Assets 26.6m / Total Current Liabilities 172.8k)
Debt / Equity = 0.00 (Debt 278.1k / totalStockholderEquity, last quarter 768.6m)
Debt / EBITDA = -0.00 (Net Debt -71.3k / EBITDA 43.5m)
Debt / FCF = -0.00 (Net Debt -71.3k / FCF TTM 70.3m)
Total Stockholder Equity = 642.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.61% (Net Income 43.5m / Total Assets 774.6m)
RoE = 6.77% (Net Income TTM 43.5m / Total Stockholder Equity 642.6m)
RoCE = -3.35% (EBIT -21.5m / Capital Employed (Equity 642.6m + L.T.Debt 0.0))
RoIC = -2.29% (negative operating profit) (NOPAT -17.0m / Invested Capital 742.1m)
WACC = 8.17% (E(1.57b)/V(1.57b) * Re(8.17%) + D(278.1k)/V(1.57b) * Rd(0.03%) * (1-Tc(0.21)))
Discount Rate = 8.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -58.80%
[DCF Debug] Terminal Value 81.04% ; FCFE base≈55.0m ; Y1≈67.8m ; Y5≈115.7m
Fair Price DCF = 30.74 (DCF Value 1.92b / Shares Outstanding 62.5m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -54.13 | EPS CAGR: -91.43% | SUE: 0.11 | # QB: 0
Revenue Correlation: -17.93 | Revenue CAGR: 67.56% | SUE: N/A | # QB: 0
Additional Sources for BMEZ Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle